# US 2016/0354491 A1 · Modified nucleic acid molecules and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354491 A1
- Document ID: US20160354491A1
- Status: Published application
- Kind: A1
- Application number: 15/240,512
- Filed: 2016-08-18
- Published: 2016-12-08
- Earliest claimed: 2012-12-13
- Assignees: Moderna Therapeutics, Inc.
- Applicants: Moderna Therapeutics, Inc.
- Inventors: Atanu ROY; Christopher R. CONLEE; Antonin DE FOUGEROLLES; Andrew W. FRALEY
- Web page: https://patentgrep.com/patent/US20160354491A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/193: {Colony stimulating factors [CSF]}
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12P 21/005: {Glycopeptides, glycoproteins}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/335: Modified T or U
- C12N 2310/336: Modified G
- C12N 2320/30: Special therapeutic applications
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

## Claims

### Claim 1

An mRNA encoding a polypeptide, wherein the mRNA comprises:
(i) at least one 5′-cap structure;
(ii) a 5′-UTR;
(iii) an open reading frame encoding the polypeptide wherein at least one nucleotide is 2-thio-uridine; and
(iv) a 3′-UTR.

### Claim 2 (depends on 1)

The mRNA of claim 1, wherein the open reading frame encoding the polypeptide and consisting of nucleotides including 2-thio-uridine, cytosine, adenine, and guanine

### Claim 3 (depends on 1)

The mRNA of claim 1, wherein the at least one 5′-cap structure is cap0, cap1, ARCA, inosine, N1-methyl-guanosine, 2′-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, or 2-azido-guanosine.

### Claim 4 (depends on 3)

The mRNA of claim 3, wherein the at least one 5′-cap structure is cap0, cap1, or ARCA.

### Claim 5 (depends on 1)

The mRNA of claim 1, wherein the 3′-UTR is an alpha-globin 3′-UTR.

### Claim 6 (depends on 1)

The mRNA of claim 1, wherein the mRNA further comprises a poly-A region

### Claim 7 (depends on 6)

The mRNA of claim 6, wherein the poly-A region is at least 160 nucleotides in length.

### Claim 8 (depends on 1)

The mRNA of claim 1, wherein the 5′-UTR comprises a Kozak sequence.

### Claim 9 (depends on 1)

The mRNA of claim 1, wherein the mRNA is purified.

### Claim 10 (depends on 1)

The mRNA of claim 1, wherein, upon administration to peripheral blood mononuclear cells, the mRNA induces detectably lower levels of IFN-α or TNF-α relative to a corresponding mRNA comprising an open reading frame consisting of nucleotides including uracil, cytosine, adenine, and guanine.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the mRNA of claim 1 and a pharmaceutically acceptable excipient.

### Claim 12 (depends on 1)

A method of expressing a polypeptide of interest in a mammalian cell, the method comprising:
(i) providing the mRNA of claim 1; and
(ii) introducing the mRNA to a mammalian cell under conditions that permit the expression of the polypeptide of interest by the mammalian cell.
